Clinical trials: Rare Malignant Neoplasm
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Cancer, Cancer Metastatic
Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)
This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers.
- Conditions
- Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation
- Trial name
- TRacKING (NCT04921553)
- Testing
- Data collection and quality of life questionnaire
- Where
- 41 sites in Austria, Czechia and 9 more
- Volunteers
- 500 people
- Sponsor
- Centre Leon Berard
Non-small Cell Lung Cancer
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X…
- Trial name
- NCT05168566
- Testing
- Sutetinib Maleate Capsule
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 128 people
- Sponsor
- Teligene US
Breast Cancer, Non-small Cell Lung Cancer
Integrated Molecular Profiling in Advanced Cancers Trial
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer
- Trial name
- IMPACT (NCT01505400)
- Where
- Canada
- Volunteers
- 3,026 people
- Sponsor
- University Health Network, Toronto
Leukemia, Hematologic Malignancy
Solving Riddles Through Sequencing
During the last decades hematologists have excelled at improving and refining the classification, diagnosis, and thus ultimately the therapeutic decision-making process for their patients.
- Conditions
- Leukemia, Hematologic Malignancy, Rare Diseases, Refractory Leukemia
- Trial name
- SIRIUS (NCT05046444)
- Testing
- Next Generation Sequencing
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Munich Leukemia Laboratory
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma
- Trial name
- NCT02721732
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer.
- Conditions
- Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia
- Trial name
- NCT00898079
- Testing
- Cytology Specimen Collection Procedure
- Where
- 192 sites in United States, Australia and 4 more
- Volunteers
- 2,545 people
- Sponsor
- Children's Oncology Group
Cancer of Unknown Primary Site
Sintilimab in Cancer of Unknown Primary
This is a Phase 2 clinical trial evaluating the efficacy and safety of sintilimab in subjects with CUP. Up to 45 subjects with CUP will be enrolled.
- Trial name
- NCT05024968
- Testing
- Sintilimab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Salivary Gland Tumor, Rare Malignant Neoplasm
PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers
The objectives of this pilot feasibility study, which is on the use of 68-Ga PSMA PET imaging of salivary gland tumours, are to determine the proportion of patients with high PSMA-ligand uptake on Ga-68 PSMA imaging in locally…
- Trial name
- NCT05581979
- Testing
- 68-Ga PSMA PET scan
- Where
- Singapore
- Volunteers
- 4 people
- Sponsor
- National Cancer Centre, Singapore
Carcinoma, Renal Cell, Head and Neck Neoplasm
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in 6 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Carcinoma, Renal Cell, Head and Neck Neoplasm, Skin Neoplasms, Microsatellite Instability
- Trial name
- AcSé (NCT03012581)
- Testing
- Nivolumab
- Where
- France
- Volunteers
- 269 people
- Sponsor
- UNICANCER
Solid Tumour, Haematological Malignancy
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT06988475)
- Testing
- Capmatinib
- Where
- 17 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Sarcoma, Malignant Mesenchymoma
The Sarcoma Biology and Outcome Project
SarcBOP - An interdisciplinary and translational registry SarcBOP aims to establish a database that integrates every aspect possibly relevant to sarcoma treatment and research.
- Conditions
- Sarcoma, Malignant Mesenchymoma, Sarcoma of Bone and Connective Tissue
- Trial name
- SarcBOP (NCT04758325)
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- Prof. Dr. Richard F Schlenk
Anaplastic Astrocytoma, Anaplastic Ependymoma
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma
- Trial name
- NCT03434262
- Testing
- Gemcitabine, ribociclib, sonidegib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Biliary Tract Cancer, Neuroendocrine Tumors
Combination Immunotherapy in Rare Cancers Under InvesTigation
The four tumour streams that will be studied in this protocol are based on immunotherapy sensitive rare cancers from CA209-538 which will be further investigated under this protocol and divided into four groups: 1.
- Conditions
- Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor
- Trial name
- MOST-CIRCUIT (NCT04969887)
- Testing
- Ipilimumab, Nivolumab
- Where
- 18 sites in Australia, New Zealand
- Volunteers
- 240 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Brain Tumors
SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence
This study focuses on rare brain tumors, which are heterogeneous entities with different morphological, biological, and clinical characteristics.
- Trial name
- SIMPLIF-AI (NCT06878469)
- Testing
- RehaCom
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
This phase II trial studies how well cobimetinib and atezolizumab work in treating participants with rare tumors that have spread to other places in the body (advanced) or that does not respond to treatment (refractory).
- Conditions
- Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion, Locally Advanced Malignant Neoplasm
- Trial name
- NCT03108131
- Testing
- Atezolizumab, Cobimetinib
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Solid Neoplasm
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
This phase II trial tests whether combination of talazoparib and temozolomide works to shrink tumors in patients with rare cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of…
- Trial name
- NCT05142241
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)